Shared REMS For Transmucosal Fentanyls Could Expand Market For Meda’s Onsolis As It Exits More Restrictive Program
This article was originally published in The Pink Sheet Daily
Class-wide Risk Evaluation and Mitigation Strategy for transmucosal immediate-release fentanyl products will begin operations in March 2012, with participants in REMS for individual products to be transitioned automatically to the new system.
You may also be interested in...
Coming Soon: New US FDA Opioid Plan
Commissioner Robert Califf said the new plan should be released in August and include prongs to continue fighting the ongoing prescription opioid epidemic, as well as confront a new synthetic fentanyl and methamphetamine problem.
Keeping Track: Neurology And Pain Products Keep FDA Occupied
The latest drug development news and highlights from our FDA Performance Tracker.
Stairway To Heaven: REMS Website Integrated With Health Care Systems
Participants in a two-day FDA meeting on REMS standardization and assessment suggested a website containing all REMS information and enrollment functions and allowing interaction with existing health records and claims systems would facilitate compliance with safety requirements.